View Older Stories View More Recent Stories

Nov 1, 2022 07:35PM Form 4 Kymera Therapeutics, For: Oct 28 Filed by: Atlas Venture Associates Opportunity I, L.P.
Oct 18, 2022 07:00AM Versanis Bio Appoints Kenneth Attie, M.D., and Aditya Venugopal, Ph.D., to Key Leadership Roles
Oct 14, 2022 06:30AM Matchpoint Therapeutics Launches with $100 Million to Deliver on the Promise of Precision Covalent Medicines for Immune Diseases
Oct 6, 2022 07:00AM Rectify Pharmaceuticals Appoints Robert Hughes as Executive Vice President, Drug Discovery and Preclinical Development, and Xiaobing Li as Chief Development Officer
Oct 5, 2022 06:00AM Valence Discovery Grows Leadership Team with Key Drug Discovery Hires
Sep 29, 2022 04:30PM Form SC 13D Third Harmonic Bio, Inc. Filed by: Atlas Venture Fund XI, L.P.
Sep 28, 2022 03:01AM Brandon Capital co-Leads USD68M Series A Financing of London-Based ADC Company Pheon Therapeutics
Sep 28, 2022 03:00AM Pheon Therapeutics Launches with $68 Million in Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Solid Tumors
Sep 21, 2022 04:59PM Form 4 Day One Biopharmaceutica For: Sep 19 Filed by: Atlas Venture Fund XI, L.P.
Sep 20, 2022 08:00AM Q32 Bio, a Clinical Stage Biotechnology Company Focused on Therapeutics that Restore Immune Homeostasis, Announces CEO Transition
Sep 20, 2022 07:33AM Generation Bio (GBIO) Appoints Phillip Samayoa as Chief Strategy Officer
Sep 20, 2022 07:30AM Generation Bio Names Phillip Samayoa, Ph.D. Chief Strategy Officer
Sep 20, 2022 07:30AM Generation Bio Names Phillip Samayoa, Ph.D. Chief Strategy Officer
Sep 19, 2022 04:52PM Form 4 Third Harmonic Bio, Inc. For: Sep 19 Filed by: Atlas Venture Associates XI, LLC
Sep 14, 2022 06:04PM Form 3 Third Harmonic Bio, Inc. For: Sep 14 Filed by: Atlas Venture Associates XI, LLC
Sep 14, 2022 05:06PM Form SC 13D/A Replimune Group, Inc. Filed by: Atlas Venture Fund X, L.P.
Sep 12, 2022 07:00AM Nimbus Therapeutics Closes $125M Private Financing to Advance Clinical Programs in Autoimmune Diseases and Oncology
Sep 8, 2022 06:00AM Photys Therapeutics Debuts with $75 Million Series A Funding to Advance New Class of Bifunctional Molecules for Precision Phosphorylation to Modulate and Repair Disease-Driving Proteins
Aug 23, 2022 07:00AM K36 Therapeutics Announces FDA Clearance of Investigational New Drug Application and Formation of Clinical Advisory Board for Lead Program KTX-1001
Aug 11, 2022 10:01AM ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox
Aug 11, 2022 08:00AM PsiOxus Therapeutics Appoints Howard Davis, Ph.D. as Chief Executive Officer
Aug 11, 2022 06:01AM Form 13F-HR Atlas Venture Advisors, For: Jun 30
Aug 11, 2022 06:01AM Form 13F-HR Atlas Venture Associates For: Jun 30
Aug 11, 2022 06:01AM Form 13F-NT Atlas Venture Associates For: Jun 30
Aug 11, 2022 06:01AM Form 13F-NT Atlas Venture Associates For: Jun 30
Aug 11, 2022 06:01AM Form 13F-NT Atlas Venture Fund VIII, For: Jun 30
Aug 10, 2022 07:30AM Gemini Therapeutics (GMTX) and Disc Medicine Announce Merger Agreement
Aug 10, 2022 07:30AM Gemini Therapeutics and Disc Medicine Announce Merger Agreement
Aug 3, 2022 07:00AM AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients
Jul 20, 2022 04:23PM Form SC 13D/A Aerovate Therapeutics, Filed by: Atlas Venture Fund XII, L.P.
Jul 20, 2022 07:00AM Versanis Bio Announces Leadership and Board Appointments as Company Prepares to Initiate Phase 2b Study with Novel Approach to Obesity
Jul 19, 2022 05:29PM Form 4 Aerovate Therapeutics, For: Jul 15 Filed by: Atlas Venture Fund XII, L.P.
Jul 7, 2022 08:00AM Kinaset Therapeutics Appoints Christopher O’Brien, MD, PhD, FCCP, as Chief Medical Officer
Jul 6, 2022 04:42PM Form 4 Day One Biopharmaceutica For: Jul 01 Filed by: Atlas Venture Opportunity Fund I, L.P.
Jun 22, 2022 05:10PM Form 4 Day One Biopharmaceutica For: Jun 17 Filed by: Atlas Venture Associates XI, L.P.
Jun 3, 2022 08:00AM Replimune Announces the Departure of Jason Rhodes from its Board of Directors
May 19, 2022 06:30AM Be Bio and Resilience Announce Strategic Collaboration to Manufacture Engineered B Cells, a New Class of Cellular Medicines
May 17, 2022 06:45AM Remix Therapeutics Closes $70 Million Series B Financing
May 16, 2022 04:02PM Form 13F-HR Atlas Venture Life Scien For: Mar 31
May 16, 2022 03:54PM Form 13F-HR Atlas Venture Life Scien For: Dec 31
May 12, 2022 01:48PM Form 13F-NT Atlas Venture Fund VIII, For: Mar 31
May 12, 2022 01:46PM Form 13F-NT Atlas Venture Associates For: Mar 31
May 12, 2022 01:44PM Form 13F-NT Atlas Venture Associates For: Mar 31
May 12, 2022 01:38PM Form 13F-HR Atlas Venture Advisors, For: Mar 31
May 12, 2022 01:37PM Form 13F-HR Atlas Venture Associates For: Mar 31
May 5, 2022 04:06PM Form SC 13D/A Aerovate Therapeutics, Filed by: Atlas Venture Fund XII, L.P.
May 5, 2022 04:02PM Form SC 13D/A Magenta Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Apr 26, 2022 07:00AM Vedere Bio II Appoints Accomplished Clinician and Researcher Anna-Maria Demetriades as Chief Medical Officer
Apr 25, 2022 08:04AM Perspective Group Announcing the Formation of an Advisory Board
Apr 19, 2022 08:00AM Sionna Therapeutics Launches with $111 Million Series B Financing to Advance Pipeline of Novel Small Molecules with the Potential to Fully Restore CFTR Function in Cystic Fibrosis
View More Recent Stories View Older Stories